3 Undervalued Life Sciences Tools & Services Stocks for Monday, November 11
Discover the top 3 undervalued Life Sciences Tools & Services stocks for Monday, November 11 based on AAII’s Stock Grades.Omar Beirat
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Omar Beirat
Omar Beirat
Jack Gilleland
Jack Gilleland
| Share Statistics | BNGO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $14.3 | $3,076.5 | 8% |
|
| Shares Out (Mil) | 11.5 | 96.5 | 22% |
|
| Institutional Ownership | 99.7% | 90.0% | 92% |
|
| Float (Mil) | 10.6 | 71.5 | 20% |
|
| Beta | 1.62 | 1.22 | 86% |
|
| Avg Daily Volume (000s) | 144 | 710 | 39% |
|
| Price Change (52-week) |
(63.0%) | 89.4% | 10% |
|
| Growth | BNGO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 27.4% | 7.8% | 88% |
|
| Net Income (5yr) | 8.5% | (13.7%) | 53% |
|
| EPS (5yr) | 54.0% | 0.7% | 94 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (15.0%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.670) | ($2.140) | ($0.970) | |
| Month Ago EPS | ($0.670) | ($2.130) | ($0.970) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.890) | ($2.710) | ($1.110) | |
| Year/Year Chg | 4.2% | (55.9%) | (89.3%) | |
| Financials | BNGO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $30 | $800 | 16% |
|
| Net Income (TTM) (Mil) | ($32) | ($31) | 20% |
|
| EPS (TTM) | ($3.371) | ($0.300) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($21) | $47 | 15% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $5 | 45% |
|
| Long-Term Debt (Q1) (Mil) | $6 | $270 | 25% |
|
| Enterprise Value (Q1) (Mil) | $11 | $3,795 | 8% |
|
| Valuation | BNGO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.45 | 3.68 | 7% |
|
| P/E | na | 39.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.5 | na |
|
| Ratios | BNGO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 47.5% | 47.7% | 59% |
|
| Net Margin | (106.6%) | (3.2%) | 7% |
|
| ROA | (52.0%) | (4.3%) | 11% |
|
| ROE | (83.6%) | (7.9%) | 11% |
|
| Liabilities to Assets | 33.6% | 42.0% | 25% |
|
| F-Score | 5 | 5 | 50% |
|
Bionano Genomics, Inc. did not pass any screens on 8/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors